1. Home
  2. XELB vs IKT Comparison

XELB vs IKT Comparison

Compare XELB & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Brands Inc.

XELB

Xcel Brands Inc.

HOLD

Current Price

$1.17

Market Cap

10.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

181.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XELB
IKT
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
181.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
XELB
IKT
Price
$1.17
$1.68
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$3.00
$4.00
AVG Volume (30 Days)
50.0K
594.0K
Earning Date
11-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,980,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$83.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$1.33
52 Week High
$7.40
$3.88

Technical Indicators

Market Signals
Indicator
XELB
IKT
Relative Strength Index (RSI) 60.60 65.77
Support Level $1.06 $1.52
Resistance Level $1.21 $1.67
Average True Range (ATR) 0.09 0.11
MACD 0.04 0.03
Stochastic Oscillator 93.71 97.14

Price Performance

Historical Comparison
XELB
IKT

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: